Catalyst Wire Dossier Catalyst Wire Dossier

MDGN-002

· Avalo Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MDGN-002, covering 2024-02-26 to 2024-02-26. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis [Phase 1]

See pricing